Research programme: viral vaccines - Valneva

Drug Profile

Research programme: viral vaccines - Valneva

Alternative Names: Chikungunya virus vaccine - Valneva; Metapneumovirus vaccine - Valneva; Yellow fever vaccine - Valneva; Zika virus vaccine - Valneva

Latest Information Update: 07 Apr 2016

Price : $50

At a glance

  • Originator Valneva
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Chikungunya virus infections; Yellow fever; Zika virus infection
  • Research Metapneumovirus infections

Most Recent Events

  • 23 Feb 2017 Valneva plans a phase I trial for Chikungunya virus infections (Prevention) and Zika virus infection (Prevention)
  • 21 Mar 2016 Research programme: viral vaccines - Valneva is available for licensing as of 21 Mar 2016. http://www.valneva.com/en/technologies/91
  • 21 Mar 2016 Early Research in Metapneumovirus-infections (Prevention) in France (unspecified route) before March 2016 (Valneva April-2016 presentation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top